These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11293563)

  • 1. A comprehensive review of the antidiabetic agent rosiglitazone.
    Glazer NB; Cheatham WW
    Clin Ther; 2001 Feb; 23(2):307-8. PubMed ID: 11293563
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
    Hofmann CA; Colca JR
    Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonhypoglycemic effects of thiazolidinediones.
    Quesada-Gómez JM; Serrano-Alferez I
    Ann Intern Med; 2001 Dec; 135(11):1007-8. PubMed ID: 11730409
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.
    Cheng-Lai A; Levine A
    Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug overview. Pioglitazone hydrochloride.
    Am J Health Syst Pharm; 2000 Jan; 57(2):124-5. PubMed ID: 10688239
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
    Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
    Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones in the treatment of type 2 diabetes.
    Pittas AG; Greenberg AS
    Expert Opin Pharmacother; 2002 May; 3(5):529-40. PubMed ID: 11996632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin-sensitizing agents].
    Kadowaki T
    Nihon Rinsho; 1999 Mar; 57(3):688-94. PubMed ID: 10199155
    [No Abstract]   [Full Text] [Related]  

  • 11. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
    Marx N; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Scharnagl H; Hombach V; Koenig W
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):283-8. PubMed ID: 12588772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glitazones: proceed with caution.
    Krische D
    West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
    [No Abstract]   [Full Text] [Related]  

  • 13. How should patients taking the discontinued diabetes drug troglitazone be managed?
    Reddy SS
    Cleve Clin J Med; 2000 Jun; 67(6):401-2, 455. PubMed ID: 10860221
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential activity of rosiglitazone enantiomers at PPAR gamma.
    Parks DJ; Tomkinson NC; Villeneuve MS; Blanchard SG; Willson TM
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3657-8. PubMed ID: 9934490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
    Arakawa K; Inamasu M; Matsumoto M; Okumura K; Yasuda K; Akatsuka H; Kawanami S; Watanabe A; Homma K; Saiga Y; Ozeki M; Iijima I
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):1984-93. PubMed ID: 9433768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rosiglitazone(BRL-49653)].
    Yonezawa N; Oka Y
    Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preclinical studies of pioglitazone (AD-4833)].
    Sugiyama Y; Odaka H; Sohda T; Ikeda H
    Nihon Rinsho; 1997 Nov; 55 Suppl():137-41. PubMed ID: 9434457
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticipated US approval for rosiglitazone and pioglitazone.
    Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical efficacy of Pioglitazone (AD-4833)].
    Kaneko T; Baba S
    Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.